Cannabis use disorder: Epidemiology and management

@article{Copeland2009CannabisUD,
  title={Cannabis use disorder: Epidemiology and management},
  author={Jan Copeland and Wendy Swift},
  journal={International Review of Psychiatry},
  year={2009},
  volume={21},
  pages={103 - 96}
}
This paper provides an overview of the epidemiology of cannabis use, cannabis use disorders and its treatment. Cannabis is the most commonly used illicit drug internationally. While use is decreasing in the developed world, it appears to be stable or increasing in developing countries and some indigenous communities. Early initiation and regular adolescent use have been identified as particular risk factors for later problematic cannabis (and other drug) use, impaired mental health, delinquency… 
Cannabis use, harms and the management of cannabis use disorder
Cannabis is the most widely used illicit drug in the world, with the highest rates of use seen in New Zealand, North America and Australia. There is evidence of a decrease in the age of commencement
Cannabis use and its associated disorders: Clinical care.
TLDR
The prevalence of cannabis use, associated disorders (eg harms with early and frequent use), and information on assessment and management are described, including technological platforms such as web-based and telephone.
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review
TLDR
Evidence has shown a decrease in the age of commencement of cannabis use in some developed countries and a prolongation of risk of initiation to cannabis use beyond adolescence among more recent users.
Acute and long-term effects of cannabis use: a review.
TLDR
Evidence indicates that frequent and prolonged use of cannabis can be detrimental to both mental and physical health.
Cannabis: Use, harms, disorder, and interventions
TLDR
The prevalence of cannabis use, its associated harms, diagnostic considerations, and a brief review of best-practice treatment are outlined.
An overview of the adverse effects of cannabis use for Canadian physicians.
TLDR
Overall, evidence for direct and long-term adverse effects of cannabis use is minimal and additional longitudinal studies will be required to better delineate unidentified effects.
The Prevalence of Cannabis Withdrawal and Its Influence on Adolescents' Treatment Response and Outcomes: A 12-Month Prospective Investigation
TLDR
Although withdrawal does not seem to be independently associated with substance use outcomes posttreatment, moderating factors such as drug problem recognition should be taken into account when formulating treatment and continuing care plans.
Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial
TLDR
Preliminary evidence is provided that low-dose short-term pericyazine may be an acceptable mode of treatment in this population of cannabis dependence and further evaluation via a randomized placebo-controlled trial is warranted.
The Interface of Cannabis Misuse and Schizophrenia-Spectrum Disorders
This chapter provides an overview of the complex ways in which cannabis misuse intersects with schizophrenia-spectrum disorders. The centrally active constituents of Cannabis sativa are discussed,
Cannabis Use in Adolescence and Young Adulthood
  • C. Coffey, G. Patton
  • Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2016
TLDR
There is a strong case for actions around early heavy adolescent users with growing evidence of health consequences, and prevention of early use, identification and treatment of early heavy users, and harm reduction through diversion of earlyheavy users away from the custodial justice system into health care are all priority responses.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 92 REFERENCES
Prevalence and correlates of cannabis use in developed and developing countries
TLDR
Early and regular cannabis use in adolescence predicts an increased risk of cannabis dependence which in turn predicts an increase risk of using other illicit drugs, and reporting symptoms of mood and psychotic disorders.
Developments in the treatment of cannabis use disorder
Purpose of review To describe recent developments in the treatment of cannabis abuse and dependence in the general and special populations. Recent findings The research literature on randomised
Cannabis use disorders in the USA: prevalence, correlates and co-morbidity
TLDR
Associations between cannabis abuse and dependence and Axis I and II disorders were strong, signaling the need for more comprehensive assessment of individuals with cannabis use disorders.
The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults.
TLDR
Cannabis use is widespread in a sample of adolescents and young adults, but the probability of developing cannabis abuse or dependence is relatively low; the natural course of cannabis use is quite variable.
Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing.
TLDR
A better understanding of the factors associated with cannabis dependence may help identify groups who have difficulties controlling use and aid the development of strategies for reducing cannabis-related harm.
Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies.
  • C. Hart
  • Medicine
    Drug and alcohol dependence
  • 2005
TLDR
Data from recent research on cannabinoids that may be relevant for the development of pharmacotherapies for cannabis dependence are reviewed because these data may provide information critical for informing relapse prevention medication development efforts.
The genetic epidemiology of cannabis use, abuse and dependence.
TLDR
The substantial evidence for the heritability of cannabis use, abuse and dependence underscore the importance of linkage and association studies that aim to find genes of etiologic significance.
Prevalence and correlates of cannabis use and dependence in young New Zealanders.
TLDR
Prevalence rates of cannabis use in young New Zealanders were found to be higher than previously reported and a history of unemployment or of violent behaviour was associated with more frequent cannabis use at age 21.
Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study
TLDR
Evidence is provided for the potential clinical utility and safety of lithium in the management of cannabis withdrawal in treatment seeking adult humans and a randomised, placebo-controlled trial is recommended.
Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone
TLDR
The data suggest that comorbid patients treated with clozapine are more likely to abstain from alcohol and cannabis use than are those treated with risperidone.
...
1
2
3
4
5
...